RX.V / BIOYF is in with another good quarter. There was a timing issue of a large $628K international order that made Q2 a little light but Q3 looks to be stellar. June and July were both $1.5M revenue months. Also, remember that Q3 is seasonally stronger for insecticide sales. I'm expecting the 2015 EPS estimate for the one analyst of $0.28 to be exceeded. The stock is trading up slightly on the report.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.